Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amitifadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 15/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 15/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amitifadine SCHEMBL79279 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL30231901 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855350 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL2855353 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL378061 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL8213058 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL12313135 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL9604846 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL29393526 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| Amitifadine SCHEMBL4552778 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12274710-B2 | Compound for regulating body weight imbalance, composition thereof and application thereof | GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD (CN) | 2025-04-15 | — | — | US | claimed |
| US-12257233-B2 | Methods | ETHISMOS RESEARCH, INC. (US) | 2025-03-25 | — | — | US | claimed |
| CN-118324651-A | Preparation method and application of chiral amide | 中国科学技术大学 | 2024-07-12 | — | — | CN | claimed |
| EP-4395772-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | Ethismos Research, Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| CN-118176001-A | Methods for preventing and treating pain and related symptoms | 埃塞斯莫斯研究股份有限公司 | 2024-06-11 | — | — | CN | claimed |
| CN-112188894-B | Compound for regulating body weight unbalance, composition and application thereof | 广州新创忆药物临床研究有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-20230090174-A1 | NOVEL METHODS | ETHISMOS RESEARCH, INC. (US) | 2023-03-23 | — | — | US | claimed |
| US-20230085440-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | ETHISMOS RESEARCH, INC. (US) | 2023-03-16 | — | — | US | claimed |
| WO-2023034293-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | ETHISMOS RESEARCH, INC. (US) | 2023-03-09 | — | — | WO | claimed |
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-11471438-B2 | Methods | ETHISMOS RESEARCH, INC. (US) | 2022-10-18 | — | — | US | claimed |
| WO-2022207950-A1 | TREATMENT FOR OBESITY | FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM) (ES) | 2022-10-06 | — | — | WO | claimed |
| US-20220193104-A1 | COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOF | GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD (CN) | 2022-06-23 | — | — | US | claimed |
| US-20220133892-A1 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | UNIV EMORY (US) | 2022-05-05 | — | — | US | claimed |
| EP-3949972-A1 | COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOF | Guangzhou Century Clinical Research Co., Ltd (CN) | 2022-02-09 | — | — | EP | claimed |
| US-20200368201-A1 | NOVEL METHODS | ETHISMOS RESEARCH, INC. | 2020-11-26 | — | — | US | claimed |
| US-20200054601-A1 | NOVEL METHODS | ETHISMOS RESEARCH, INC. | 2020-02-20 | — | — | US | claimed |
| US-9566264-B2 | Combinations and methods | EUTHYMICS BIOSCIENCE, INC. (US) | 2017-02-14 | — | — | US | claimed |
| US-20150005359-A1 | NOVEL COMBINATIONS AND METHODS | ETHISMOS RESEARCH, INC. | 2015-01-01 | — | — | US | claimed |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | DOV PHARMACEUTICAL, INC. | 2008-03-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090174-A1 | NOVEL METHODS | ADH1C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADH1A | SLC6A2 1262/4885SLC6A4 800/4885SLC6A3 468/4885 |
| US-12257233-B2 | Methods | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADH1C, HSD3B1 | SLC6A2 527/4885SLC6A4 385/4885SLC6A3 196/4885 |
| US-20080058535-A1 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1 ARYL-3-AZABICYCLO[3.1.0]HEXANES | CYP1B1, CYP2B6, CYP2D6 | SLC6A2 3023/4885SLC6A4 2230/4885SLC6A3 982/4885 |
| US-12274710-B2 | Compound for regulating body weight imbalance, composition thereof and application thereof | WNK1, DKK1, WNK2 | SLC6A2 2182/4885SLC6A4 1522/4885SLC6A3 742/4885 |
| US-20230085440-A1 | METHODS OF PREVENTING AND TREATING PAIN AND ASSOCIATED SYMPTOMS | KCNN3, KCNN2, KCNN1 | SLC6A2 71/4885SLC6A4 43/4885SLC6A3 103/4885 |
| US-20220193104-A1 | COMPOUND FOR REGULATING BODY WEIGHT IMBALANCE, COMPOSITION THEREOF AND APPLICATION THEREOF | WNK1, DKK1, WNK2 | SLC6A2 2182/4885SLC6A4 1522/4885SLC6A3 742/4885 |
| US-20200054601-A1 | NOVEL METHODS | CHRNA5, CHRNB3, CHRNA3 | SLC6A2 103/4885SLC6A4 117/4885SLC6A3 31/4885 |
| US-11471438-B2 | Methods | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADH1C, HSD3B1 | SLC6A2 527/4885SLC6A4 385/4885SLC6A3 196/4885 |
| US-20220133892-A1 | Chimeric Compounds and Methods of Managing Neurological Disorders or Conditions | MAOA, HNMT, HDAC6 | SLC6A2 87/4885SLC6A4 165/4885SLC6A3 179/4885 |
| US-20200368201-A1 | NOVEL METHODS | ADH1C, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ADH1A | SLC6A2 1262/4885SLC6A4 800/4885SLC6A3 468/4885 |
| US-20150005359-A1 | NOVEL COMBINATIONS AND METHODS | SIGMAR1, ADH1C, ADH1A | SLC6A2 530/4885SLC6A4 179/4885SLC6A3 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.